share_log

科濟藥業-B：自願公告 – 於2024年EHA年會上呈列賽愷澤II期臨床試驗和CT071首次人體試驗的研究成果更新

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - UPDATED PHASE II RESULTS ON ZEVOR-CEL AND FIRST-IN-HUMAN CT071 RESULTS PRESENTED AT THE EHA 2024 ANNUAL CONGRESS

Hong Kong Stock Exchange ·  Jun 16 20:00
Summary by Moomoo AI
科濟藥業-B（股份代號：2171）於2024年歐洲血液學協會（EHA）年會上，公佈了旗下兩款CAR-T細胞產品的最新臨床試驗成果。賽愷澤®（CT053）是一款針對BCMA的自體CAR-T細胞產品，用於治療復發或難治性多發性骨髓瘤，其II期臨床試驗結果於6月15日進行口頭報告。CT071則是一款針對GPRC5D的自體CAR-T細胞候選產品，其I期臨床試驗初步結果於6月14日以壁報形式展示。賽愷澤®已於2024年2月獲國家藥品監督管理局批准上市，並正在北美進行1b/2期臨床試驗。CT071目前在中國開展多項臨床試驗。科濟藥業專注於血液惡性腫瘤和實體瘤的CAR-T細胞療法，旨在提高治療安全性、療效及降低成本。
科濟藥業-B（股份代號：2171）於2024年歐洲血液學協會（EHA）年會上，公佈了旗下兩款CAR-T細胞產品的最新臨床試驗成果。賽愷澤®（CT053）是一款針對BCMA的自體CAR-T細胞產品，用於治療復發或難治性多發性骨髓瘤，其II期臨床試驗結果於6月15日進行口頭報告。CT071則是一款針對GPRC5D的自體CAR-T細胞候選產品，其I期臨床試驗初步結果於6月14日以壁報形式展示。賽愷澤®已於2024年2月獲國家藥品監督管理局批准上市，並正在北美進行1b/2期臨床試驗。CT071目前在中國開展多項臨床試驗。科濟藥業專注於血液惡性腫瘤和實體瘤的CAR-T細胞療法，旨在提高治療安全性、療效及降低成本。
In the 2024 annual meeting of the European Hematology Association (EHA), Keji Pharmaceuticals-B (stock code: 2171) announced the latest clinical trial results of two CAR-T cell products under its umbrella. CT053, a CAR-T cell product targeting BCMA, is used to treat relapsed or refractory multiple myeloma, and its phase II clinical trial results were orally presented on June 15. CT071 is a CAR-T cell candidate product targeting GPRC5D, and its preliminary results from the phase I clinical trial were presented in poster format on June 14. CT053 has been approved for marketing by the National Medical Products Administration in February 2024 and is currently undergoing phase 1b/2 clinical trials in North America. Multiple clinical trials of CT071 are currently being conducted in China. Keji Pharmaceuticals focuses on CAR-T cell therapy for hematologic malignancies and solid tumors, aiming to improve treatment safety, efficacy, and reduce costs.
In the 2024 annual meeting of the European Hematology Association (EHA), Keji Pharmaceuticals-B (stock code: 2171) announced the latest clinical trial results of two CAR-T cell products under its umbrella. CT053, a CAR-T cell product targeting BCMA, is used to treat relapsed or refractory multiple myeloma, and its phase II clinical trial results were orally presented on June 15. CT071 is a CAR-T cell candidate product targeting GPRC5D, and its preliminary results from the phase I clinical trial were presented in poster format on June 14. CT053 has been approved for marketing by the National Medical Products Administration in February 2024 and is currently undergoing phase 1b/2 clinical trials in North America. Multiple clinical trials of CT071 are currently being conducted in China. Keji Pharmaceuticals focuses on CAR-T cell therapy for hematologic malignancies and solid tumors, aiming to improve treatment safety, efficacy, and reduce costs.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more